Stonegate Capital Partners updated its valuation of AB Science's stock to a mid-point of €4.25 per share, based on a discounted cash flow model following AB Science's 2025 full-year results. The firm's focus is on AB Science's lead drug masitinib for ALS, with a Phase 3 trial showing promising survival benefits, and AB8939 for acute myeloid leukemia, which has shown early positive responses. AB Science ended 2025 with €10.2M cash, improved operating losses, and secured clinical trial insurance for its ALS study. Stonegate notes potential upside if regulatory risks decrease, possibly raising the valuation midpoint to €8.50 per share.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
